With the development of liquid biopsy strategies, analyzing circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA), the presence of TP53 mutations can be detected throughout the natural history of disease and may serve as a prognostic biomarker, guiding clinical decision-making regarding early treatment intensification strategies in patients with a potentially highly aggressive disease. This evidence concerns the gene TP53 and neoplasm.